Trial Profile
A multicenter, single-arm, phase II study to evaluate a safety and efficacy of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed/refractory Waldenström Macroglobulinemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms OBI-1
- 15 Jun 2023 Status changed from recruiting to completed, according to a Results presented at the 28th Congress of the European Haematology Association.
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association
- 06 Dec 2022 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified November 2018).